Search Results - "JOHANSEN, NICKLAS"

A Systematic Review on Insulin Overdose Cases: Clinical Course, Complications and Treatment Options by Johansen, Nicklas Järvelä, Christensen, Mikkel Bring

“…A large overdose of insulin is a serious health matter. Information concerning administration and duration of intravenous (IV) glucose, other treatment options…”
Get full text

The potential of colchicine for lowering the risk of cardiovascular events in type 1 diabetes by Johansen, Nicklas Järvelä, Knop, Filip Krag

“…Abstract In type 1 diabetes, average life expectancy is reduced by ˃10 years as compared with outside of diabetes. Residual cardiovascular risk defines high…”
Get full text

Dasiglucagon Treatment for Postprandial Hypoglycemia After Gastric Bypass: A Randomized, Double-Blind, Placebo-Controlled Trial by Nielsen, Casper K., Øhrstrøm, Caroline C., Houji, Inas J.K., Helsted, Mads M., Krogh, Liva S.L., Johansen, Nicklas J., Hartmann, Bolette, Holst, Jens J., Vilsbøll, Tina, Knop, Filip K.

“…OBJECTIVE Postbariatric hypoglycemia affects >50% of individuals who have undergone Roux-en-Y gastric bypass surgery. Despite the often debilitating nature of…”
Get full text

Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial by Johansen, Nicklas J, Dejgaard, Thomas F, Lund, Asger, Schlüntz, Camilla, Frandsen, Christian S, Forman, Julie L, Wewer Albrechtsen, Nicolai J, Holst, Jens J, Pedersen-Bjergaard, Ulrik, Madsbad, Sten, Vilsbøll, Tina, Andersen, Henrik U, Knop, Filip K

“…In type 2 diabetes, long-acting GLP-1 receptor agonists lower fasting plasma glucose and improve glycaemic control via their insulinotropic and glucagonostatic…”
Get full text

Effects of short‐acting exenatide added three times daily to insulin therapy on bone metabolism in type 1 diabetes by Johansen, Nicklas J., Dejgaard, Thomas F., Lund, Asger, Schlüntz, Camilla, Hartmann, Bolette, Holst, Jens J., Vilsbøll, Tina, Andersen, Henrik U., Knop, Filip K.

“…Aim To evaluate the efficacy of the short‐acting glucagon‐like peptide‐1 receptor agonist, exenatide, added to insulin therapy in type 1 diabetes on bone…”
Get full text

1192-P: Robust Arginine-Stimulated Glucagon Secretion in Patients with Type 1 Diabetes Independent of Diabetes Duration, Age, HbA1c, and Beta-Cell Secretory Capacity by WARNØE, JULIE, JOHANSEN, NICKLAS J., LUND, ASGER, BAGGER, JONATAN I., WEWER ALBRECHTSEN, NICOLAI J., HARTMANN, BOLETTE, HOLST, JENS J., VILSBØLL, TINA, ANDERSEN, HENRIK U., DEJGAARD, THOMAS F., KNOP, FILIP K.

“…In type 1 diabetes (T1D), the counterregulatory glucagon response to hypoglycemia disappears over time. It remains unknown whether this is due to lack of…”
Get full text

The efficacy and safety of exenatide once weekly in patients with type 2 diabetes by Heimbürger, Sebastian M, Brønden, Andreas, Johansen, Nicklas J, Dejgaard, Thomas F, Vilsbøll, Tina, Knop, Filip K

“…Exenatide once weekly (QW) is a glucagon-like peptide 1 receptor agonist (GLP-1RA) that was approved in 2012 in Europe and the U.S.A. for the treatment of type…”
Get more information

1094-P: Short-Acting Exenatide and Markers of Cardiovascular Disease in Type 1 Diabetes: A Randomized, Double-Blinded, Placebo-Controlled Trial by JOHANSEN, NICKLAS J., DEJGAARD, THOMAS F., LUND, ASGER, SCHLÜNTZ, CAMILLA, LARSEN, EMIL LIST, POULSEN, HENRIK E., GØTZE, JENS P., MØLLER, HOLGER, VILSBØLL, TINA, ANDERSEN, HENRIK U., KNOP, FILIP K.

“…In type 2 diabetes, some glucagon-like peptide 1 receptor agonists (GLP-1RAs) reduce the risk of major adverse cardiovascular events. Whether GLP-1RAs have any…”
Get full text

Protocol for Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetes Cases (The MAG1C trial): a randomised, double-blinded, placebo-controlled trial by Johansen, Nicklas Järvelä, Dejgaard, Thomas Fremming, Lund, Asger, Vilsbøll, Tina, Andersen, Henrik Ullits, Knop, Filip Krag

“…IntroductionPersons with type 1 diabetes require intensive insulin therapy to achieve glycaemic control, but side effects, including hypoglycaemia and weight…”
Get full text

Effect of short‐acting exenatide administered three times daily on markers of cardiovascular disease in type 1 diabetes: A randomized double‐blind placebo‐controlled trial by Johansen, Nicklas J., Dejgaard, Thomas F., Lund, Asger, Schlüntz, Camilla, Larsen, Emil L., Poulsen, Henrik E., Goetze, Jens P., Møller, Holger J., Vilsbøll, Tina, Andersen, Henrik U., Knop, Filip K.

“…Aims To investigate the effect of adding the short‐acting glucagon‐like peptide 1 receptor agonist (GLP‐1RA) exenatide to insulin treatment on markers of…”
Get full text

Prophylactic antibiotics at the time of tracheotomy lowers the incidence of pneumonia by Johansen, Nicklas Järvelä, Hahn, Christoffer Holst

“…Nosocomial pneumonia in relation to tracheotomy is a well-known complication. The aim of the present study was to study prophylactic antibiotics at the time of…”
Get full text

Coming Closer to Citizens? Frustrated Dialogue on the Danish Health Authority's Facebook Page During COVID-19 by Madvig, Fie, Achiam, Marianne, Adler-Nissen, Rebecca, Johansen, Nicklas, Whiteley, Louise

“…As the COVID-19 pandemic began, health authorities rushed to use social media to communicate information and persuade citizens to follow guidelines. Yet a…”
Get full text

1685-P: Dapiglutide Is a Dual Agonist on Human GLP-1- and GLP-2-Receptors with a Biased and Prolonged Signaling Profile at the GLP-1R by Gjelstrup, Louise, Lundholt, Betina Kerstin, Larsen, Bjarne D, Johansen, Nicklas J, Olsen, Minna B, Mathiesen, Jesper M

“…Dapiglutide, a potential first-in-class therapy targeting obesity and low-grade inflammation, is designed for activating both GLP-1 and GLP-2 receptors. In a…”
Get full text

Abstract 9392: Cardiovascular, Metabolic and Safety Outcomes With Semaglutide by Age: A Post Hoc Analysis of SUSTAIN 6 and PIONEER 6 by Petrie, Mark, Bain, Stephen, Hoff, Soren Tetens, Johansen, Nicklas, Rasmussen, Søren, Vilsboell, Tina, Husain, Mansoor

“…IntroductionFor older patients with type 2 diabetes, treatments that minimize the risk of hypoglycemia and provide benefits in terms of comorbidities, while…”
Get full text

801-P: Short-Acting Exenatide Added Three Times Daily to Insulin Therapy Improves Fatty Liver Index in Type 1 Diabetes by JOHANSEN, NICKLAS, DEJGAARD, THOMAS F., LUND, ASGER, NIELSEN, CASPER K., VILSBØLL, TINA, KNOP, FILIP K.

“…Fatty liver index (FLI), a marker of hepatic fat content, has been reported as an independent risk factor for all-cause mortality and major cardiovascular…”
Get full text

745-P: Short-Acting Exenatide Added Three Times Daily to Insulin Therapy Improves Insulin Sensitivity in Type 1 Diabetes by JOHANSEN, NICKLAS, DEJGAARD, THOMAS F., LUND, ASGER, VILSBØLL, TINA, ANDERSEN, HENRIK U., KNOP, FILIP K.

“…Average life expectancy in type 1 diabetes is reduced by more than a decade due to cardiovascular (CV) disease. Reduced insulin sensitivity as assessed by low…”
Get full text

734-P: The Effect of Adjunctive Therapy with Liraglutide on Insulin Sensitivity in Overweight Persons with Type 1 Diabetes by DEJGAARD, THOMAS F., FRANDSEN, CHRISTIAN S., JOHANSEN, NICKLAS, MADSBAD, STEN, KNOP, FILIP K., ANDERSEN, HENRIK U.

“…Type 1 diabetes is associated with an almost threefold higher mortality rate than the general population, primarily driven by excess mortality from…”
Get full text

IL-6 Inhibitor Ziltivekimab Increases Serum Hemoglobin and Iron Biomarkers in Patients with CKD Stage 3-5: A RESCUE Trial Analysis: PO0484 by Pergola, Pablo E., Davidson, Michael, Devalaraja, Matt, Ivkovic, Milana, Johansen, Nicklas J., Raj, Dominic S., Sode, Birgitte F., Tuttle, Katherine R., Perkovic, Vlado

Get full text

Kaki: Efficient Concurrent Update Synthesis for SDN by Johansen, Nicklas S., Kær, Lasse B., Madsen, Andreas L., Nielsen, Kristian Ø., Srba, Jiří, Tollund, Rasmus G.

“…Modern computer networks based on the software-defined networking (SDN) paradigm are becoming increasingly complex and often require frequent configuration…”
Get full text

FBR: Dynamic Memory-Aware Fast Rerouting by Johansen, Nicklas S., Kar, Lasse B., Madsen, Andreas L., Nielsen, Kristian O., Schmid, Stefan, Srba, Jiri, Tollund, Rasmus G.

“…Modern internet communication networks, such as MPLS networks, provide fast rerouting mechanisms in the data plane in order to quickly react to link failures…”
Get full text